NCT01098981View on ClinicalTrials.gov

Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke

PHASE3TerminatedINTERVENTIONAL
Enrollment

675

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Acute Ischemic Stroke
Interventions
DEVICE

Transcranial ultrasound as an adjunctive therapy to tPA

"* tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with active insonation for 120 minutes"

DRUG

Standard of care tPA therapy for acute ischemic stroke

"* tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with sham (inactive) insonation for 120 minutes"

Trial Locations (1)

98052-2431

Cerevast Therapeutics, Inc., Redmond

Sponsors
All Listed Sponsors
lead

Cerevast Therapeutics, Inc.

INDUSTRY